Basel’s business card comes with a lab

A scientist with a promising molecule and an overseas executive hunting for laboratory space have different to-do lists. In the Basel Area, they can start with the same organization. Basel Area Business & Innovation helps companies find premises, meet local decision-makers and turn research into businesses. It also operates innovation campuses. The introduction and the place to use it come from the same address book.

That is a more interesting proposition than the agency’s long name suggests. Its territory covers the Swiss cantons of Basel-Stadt, Basel-Landschaft and Jura. Its clients range from early scientific ventures to established manufacturers and international companies. The common problem is practical: knowing which person, institution or program can get the next piece of work done.

The organization is a nonprofit with a regional-development mandate. Its return is supposed to show up in the region: companies established, capabilities developed, investment attracted. That helps explain why it can offer relocation advice free of charge. The business taking the advice is a beneficiary; the cantons have a reason to pay.

Three organizations. One front door.

The arrangement began with a merger, rather than a lone founder’s flash of inspiration. BaselArea, i-net innovation networks switzerland and China Business Platform were brought together, with operations starting on January 1, 2016. Christof Klöpper took operational charge, and Domenico Scala became president. Eighteen employees came from the existing organizations.

The founding budget was approximately CHF 3.8 million for 2016, funded by the three cantons and the federal State Secretariat for Economic Affairs. The announcement envisaged about CHF 3.6 million annually from 2017. Those are historical operating figures, useful for understanding the undertaking’s starting scale.

The first annual report described the unglamorous work behind the merger: combining three teams, three service portfolios and three public identities while making savings. That is the documented early difficulty. The regional implementation plan also favored actively finding companies and guiding them through connected services. The lesson was organizational: an event, a workshop and confidential advice should lead somewhere together.

By April 2020, the agency had adopted the name Basel Area Business & Innovation. Its current service menu is shorter: Land, Launch and Level up. Each verb describes a business situation. Behind them sit different teams, programs and eligibility rules.

The welcome is free. The move has a budget.

Land helps companies evaluate the region, look for sites, meet authorities and establish operations. A tailored visit can bring potential peers and local specialists into the conversation before a company commits to premises. The service covers laboratory and office searches as well as introductions relevant to incorporation.

There is a useful boundary around that promise. The agency’s support is free; the legal, fiduciary and other experts it introduces can charge for their work. A founder still needs to budget for the company being built. Free navigation does not make the destination free.

“The earlier you connect with Basel Area Business & Innovation, the better.”

Nicolas Chornet · Former manufacturing executive, Moderna

Neurocrine Biosciences describes support with its Swiss expansion and coordination with local authorities. Moderna’s former manufacturing executive Nicolas Chornet recommends making contact early. These are customer endorsements, but they reveal the job being purchased with public money: helping a newcomer understand an unfamiliar place and reach the people who can act.

The cheque comes with company-building homework

BaseLaunch, introduced in 2017, takes the agency into the details of creating biotech businesses. Selected ventures can receive up to CHF 500,000, alongside help with scientific strategy, intellectual property, team formation and business development. Its listed partners include Roche, AbbVie, CSL, Johnson & Johnson, Novo Nordisk and Pureos Bioventures.

The financing is a convertible loan. BaseLaunch says founders retain control over whether it converts, and support is structured around development and business milestones agreed individually. Ventures need a corporate presence in the Basel region. The program does not demand personal financial guarantees or rights to the venture’s intellectual property.

That combination addresses a specific gap between interesting research and a company investors can assess. An experiment may need funding before a conventional financing round is realistic. A licensing question or missing executive can hold things up just as effectively. BaseLaunch works on those pieces together, with support tailored to the project rather than a fixed cohort curriculum.

Alentis Therapeutics makes the process tangible. Its research roots lie in Thomas Baumert’s laboratory in Strasbourg; the company’s launch announcement credits BaseLaunch with early financial and operational support. BaseLaunch’s account describes help licensing IP, assembling the initial team and supporting Series A financing.

“Alentis would not exist without it,” Baumert says in the program’s published account. In November 2024, Alentis raised $181.4 million in a Series D financing led by OrbiMed, with Novo Holdings and Jeito Capital as co-leads. That later round belongs to Alentis. The agency’s contribution was earlier, when the venture’s foundations were still being assembled.

A healthtech founder needs a different door

DayOne serves technologies that help pharmaceutical research and development: tools for discovery, biomarkers, data and clinical-trial work. Its three-month accelerator combines coaching with access to industry expertise. Selected graduates can receive up to CHF 50,000 in non-dilutive funding and six months of workspace. Participation is fee-free and equity-free.

The distinction from BaseLaunch matters. DayOne explicitly excludes companies developing their own therapeutic asset pipelines. A technology useful to pharma is not automatically a drug company, and the questions each must answer differ. DayOne helps founders sharpen a proposition that a pharmaceutical partner can evaluate and potentially test.

For founders earlier in the process, VentureConnect offers a less scheduled starting point. Science and technology startups connected to the Basel Area can seek coaching, meet peers and explore service vouchers without waiting for an accelerator cohort. It does not directly fund companies. Its co-founder matchmaking events address another basic need: finding someone who wants to build the business with you.

Jura brings the factory into the conversation

The manufacturing side prevents this from becoming an exclusively pharmaceutical story. InnoJura Accelerator builds on the earlier i4Challenge and DayOne Tech initiatives. The agency describes the change as a way to give startups and SMEs a clearer entry point and more coherent support.

Industrial and medtech startups receive coaching, group sessions and bootcamps to prepare for partnerships with established manufacturers. The advertised offer includes up to CHF 40,000 of in-kind support. Additional location-linked benefits depend on establishing in Jura or willingness to relocate there. The next step can be the InnoJura Platform, where startups and SMEs work toward joint solutions.

Established businesses approach through Level up. OneCoach, GroupCoach and related programs support strategy, peer exchange and collaboration. Here, the agency says it helps SMEs identify funding opportunities rather than providing direct funding itself. A production business seeking technical expertise therefore enters a different conversation from a biotech founder seeking a loan.

Digital Accelerator Basel adds a deliberately small route for digital technology ventures: four places and one theme each year. It targets startups with prototypes or proofs of concept ready for customer testing, with work on pricing, IP and industry connections. The annual theme and limited capacity are real selection constraints.

Put the advice near the equipment

The agency operates three Switzerland Innovation Park Basel Area sites: Main Campus in Allschwil, Novartis Campus in Basel and Jura Campus. Life sciences and digital health feature in the first two locations; industrial innovation gives Jura its particular role. This puts physical space alongside the organization’s advisory and program work.

That mix distinguishes its offer from hiring a private incorporation adviser or applying to a stand-alone accelerator. A company can work across location questions, venture support and workspace within the same organization. The advantage depends on the local institutions and expertise being relevant to its business.

The people providing the service reflect that breadth. The careers page describes more than 50 employees from over ten nationalities, English as the main working language and hybrid working. It presents collaboration, trust and curiosity as cultural priorities. Those are the employer’s own claims, but the international working language fits an organization courting companies across borders.

Bring a bottleneck, then ask for the next step

The first-decade totals reported by the agency exceed 300 supported settlements, 650 company foundations and CHF 950 million raised by supported startups. They indicate reach, although they do not isolate what would have happened without assistance. Portfolio fundraising measures money raised by companies; it does not measure the agency’s revenue.

A practical way to use the offer is to arrive with a specific obstacle. A company considering Switzerland can ask for relevant site visits. A scientific founder can identify the experiment or licensing issue holding back financing. An SME can describe the production problem it wants a partner to help solve. Each request gives an adviser something concrete to organize.

For other regions, the copyable idea is the connection between services: make introductions lead to expertise, expertise lead to a project, and space available when the project needs it. The conditions matter. Basel’s model relies on a regional mandate, sustained backing and relevant industrial and research partners. A company outside those networks or program criteria may be better served elsewhere. Start with the fit, then pick the door.